Non-allergic rhinitis is more irritating than harmful, it can make you uncomfortable. It requires allergy skin or blood tests. There were 4448 and 3618 children participating in 2001 and 1995, respectively. The prevalence of life-time rhinitis (42.4% vs. 38.9%, p < 0.01), current rhinitis (37.4% vs. 35.1%, p < 0.03), current rhinoconjunctivitis (17.2 vs. 13.6%, p < 0.01) and life-time eczema (30.7% vs. 28.1%, p = 0.01) increased significantly.Non allergic rhinitis is more common in children than adults and is one of the major chronic conditions in children <18 years old. In 80% of cases, it develops before the age of 20 years. Prevalence is greater in boys than girls, but there is little difference between the sexes in adulthood. Symptoms tend to improve with age, particularly in those who have an early onset of the disease.
Patients with renal insufficiency, hepatic insufficiency, or both are prone to augmentation of adverse events, resulting from a reduced clearance through renal and/or hepatic pathways. Fortunately, many of the drugs recommended for use in nonallergic rhinitis are administered intranasally. Therefore, subsequent systemic absorption is minimal. Still, antihistamines and some sympathomimetics are administered systemically. Allergic rhinitis is responsible for at least $1.8 billion annually for the direct cost of physician visits and medication expenses, or nearly 2.5 percent of the $47 billion annual direct cost for respiratory treatment. Moreover, the estimated value of lost productivity to employers and society resulting from allergic rhinitis approaches nearly $3.8 billion annually. In the mid-1990s the resulting total annual cost for allergic rhinitis amounted to $5.6 billion.